26 completed, 5 terminated, 1 unknown, 1 withdrawn. 19 Phase 2, 8 Phase 1, 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 14, Terminated 4, Unknown 1 |
| Phase 1 | 8 | Completed 5, Terminated 2, Withdrawn 1 |
| Phase 3 | 8 | Completed 8 |
Follow Human Genome Sciences Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis Belimumab, Mycophenolate Mofetil, Placebo Infusion - Systemic Sclerosis | Phase 2 | Completed | Hospital for Special Surgery, New York | 20 | 2012-08-01 | 2022-05-24 |
| BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115 Belimumab - Systemic Lupus Erythematosus | Phase 3 | Completed | GlaxoSmithKline | 142 | 2012-06-11 | 2020-03-27 |
| Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis HGS1025, Placebo - Ulcerative Colitis | Phase 1 | Withdrawn | Human Genome Sciences Inc. | 2011-12-01 | 2013-08-02 | |
| GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia Belimumab, Placebo - Systemic Lupus Erythematosus | Phase 3 | Completed | GlaxoSmithKline | 709 | 2011-05-23 | 2019-10-04 |
| Study of Belimumab Administered Subcutaneously to Healthy Subjects Single Dose Group: Belimumab IV 240 mg, Single Dose Group: Belimumab SC 2 x 120 mg, Single Dose Group: Belimumab SC 1 x 240 mg - Healthy | Phase 1 | Completed | Human Genome Sciences Inc. | 118 | 2011-02-01 | 2013-08-07 |
| Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer mapatumumab, cisplatin, radiotherapy - Advanced Cervical Cancer | Phase 1 / Phase 2 | Completed | University Medical Center Groningen | 9 | 2010-03-01 | 2024-04-19 |
| Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome Belimumab - Sjögren's Syndrome | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 20 | 2010-03-01 | 2012-07-03 |
| Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant Belimumab - Desensitization | Phase 2 | Terminated | University of Pennsylvania | 8 | 2010-02-01 | 2017-06-12 |
| A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Belimumab - Symptomatic Waldenstroms Macroglobulinaemia | Phase 2 | Unknown | Cancer Trials Australia | 15 | 2009-11-01 | 2012-02-10 |
| A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies HGS1029 - Lymphoid Malignancies | Phase 1 | Terminated | Human Genome Sciences Inc. | 11 | 2009-10-01 | 2013-08-02 |
| Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects albinterferon alfa-2b, Pegasys® - Chronic Hepatitis B | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 141 | 2009-07-01 | 2011-01-06 |
| Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76 Belimumab 1 mg/kg, Belimumab 10 mg/kg, Placebo - Systemic Lupus Erythematosus | Completed | GlaxoSmithKline | 1016 | 2009-07-01 | 2013-09-16 | |
| Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE) Belimumab 100 mg SC - Systemic Lupus Erythematosus | Phase 2 | Terminated | Human Genome Sciences Inc. | 56 | 2008-10-01 | 2013-08-07 |
| Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients alb-interferon alfa 2b, peg-interferon - Chronic Hepatitis C | Phase 2 | Completed | Novartis | 525 | 2008-10-01 | 2016-11-16 |
| A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors HGS1029 - Advanced Solid Tumors | Phase 1 | Completed | Human Genome Sciences Inc. | 66 | 2008-05-01 | 2013-11-07 |
| A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects placebo, raxibacumab - Healthy | Phase 3 | Completed | Human Genome Sciences Inc. | 322 | 2008-03-01 | 2018-11-15 |
| An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection Raxibacumab - Therapeutic Treatment of Inhalation Anthrax | Phase 2 / Phase 3 | Completed | Human Genome Sciences Inc. | 20 | 2008-01-31 | 2018-11-29 |
| A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Placebo, Belimumab 1 mg/kg, Belimumab 10 mg/kg - Systemic Lupus Erythematosus | Phase 3 | Completed | Human Genome Sciences Inc. | 865 | 2007-05-01 | 2016-12-12 |
| Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3 albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin - Chronic Hepatitis C | Phase 3 | Completed | Human Genome Sciences Inc. | 933 | 2007-02-01 | 2013-08-08 |
| A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer Mapatumumab, Paclitaxel, Carboplatin - Non Small Cell Lung Cancer | Phase 2 | Completed | Human Genome Sciences Inc. | 111 | 2007-01-01 | 2013-08-08 |
Showing 20 of 33. Sign in to see all of them.
Lupus Erythematosus, Systemic (9) · Hepatitis C (5) · Hepatitis C, Chronic (5) · Autoimmune Diseases (4) · Arthritis, Rheumatoid (2) · Bronchiolitis Obliterans Syndrome (2) · Carcinoma, Non-Small-Cell Lung (2) · Hepatitis (2) · Colitis, Ulcerative (1) · HIV Infections (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Immune System Diseases (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1)
belimumab (15) · Ribavirin (5) · mapatumumab (5) · albuferon (3) · peginterferon alfa-2a (3) · raxibacumab (2) · Antibodies (1) · Bortezomib (1) · Carboplatin (1) · Cisplatin (1) · Mycophenolic Acid (1) · Paclitaxel (1) · Radiotherapy (1) · albinterferon alfa-2b (1)
United States (19) · Canada (8) · Australia (7) · Poland (7) · France (6) · Germany (6) · India (5) · Romania (5) · United Kingdom (5) · Israel (4) · South Korea (4) · Spain (4) · Taiwan (4) · Czechia (3) · Italy (3)
Ali Naji, MD, Ph D (1) · An KL Reyners, MD,PhD (1) · Andrew Spencer (1) · David Ritchie (1) · Gilles Gallant, B. Pharm.,Ph.D. (1) · Robert Spiera, MD (1) · Xavier Mariette, PhD (1)
PMID 34628605, PMID 34741731, PMID 34531304, PMID 23213069, PMID 31302695, PMID 38216728, PMID 39115551, PMID 39208825, PMID 22275291, PMID 22337213, PMID 23524886, PMID 23681782, PMID 23754628, PMID 25396065, PMID 32918459, PMID 33568389, PMID 33687069, PMID 33830377, PMID 35302581, PMID 37228028, PMID 38258369, PMID 38724182, PMID 38775637, PMID 40256631, PMID 10398604, PMID 18666223, PMID 18786258, PMID 19447518, PMID 19587338, PMID 19714604, PMID 19714615, PMID 20039404, PMID 20600013, PMID 20600017, PMID 21296403, PMID 22127708, PMID 22674457, PMID 22707609, PMID 22863266, PMID 23547209, PMID 24187095, PMID 24560012, PMID 24995515, PMID 26336930, PMID 26639390, PMID 29073351, PMID 29409143, PMID 34215703, PMID 35428697, PMID 38140854
2009 (1)